Related Experiment Video
Updated: Nov 17, 2025
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
Identification of a serum biomarker signature associated with metastatic prostate cancer
Venera Kuci Emruli1, Leena Liljedahl1, Ulrika Axelsson1
1Department of Immunotechnology and CREATE Health Translational Cancer Center, Lund University, Lund, Sweden.
Purpose:
Improved early diagnosis and determination of aggressiveness of prostate cancer (PC) is important to select suitable treatment options and to decrease over-treatment. The conventional marker is total prostate specific antigen (PSA) levels in blood, but lacks specificity and ability to accurately discriminate indolent from aggressive disease.
Experimental Design:
In this study, we sought to identify a serum biomarker signature associated with metastatic PC. We measured 157 analytes in 363 serum samples from healthy subjects, patients with non-metastatic PC and patients with metastatic PC, using a recombinant antibody microarray.
Results:
A signature consisting of 69 proteins differentiating metastatic PC patients from healthy controls was identified.
Conclusions And Clinical Relevance:
The clinical value of this biomarker signature requires validation in larger independent patient cohorts before providing a new prospect for detection of metastatic PC.
